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ABSTRACT: We report site-specific binding constants for the intercalating anticancer drug actinomycin D 
(Act-D), binding to a 139-base-pair restriction fragment from pBR 322 DNA. The binding constants are 
derived from analysis of footprinting experiments, in which the radiolabeled 139-mer is cleaved using DNase 
I, the cleavage products undergo gel electrophoresis, and, from the gel autoradiogram, spot intensities, 
proportional to amounts of cleaved fragments, are measured. A bound drug prevents DNase I from cleaving 
at  -7 bonds, leading to decreased amounts of corresponding fragments. With the radiolabel on the 3’ end 
of the noncoding strand (A-label), we measured relative amounts of 54 cleavage products at  25 Act-D 
concentrations. For cleavage of the 139-mer with the label on the 3’ end of the coding strand (G-label), 
relative amounts of 43 cleavage products at 11 Act-D concentrations were measured. These measurements 
give information about - 120 base pairs of the restriction fragment (- 12 turns of the DNA helix); in this 
region, 14 strong and weak Act-D binding sites were identified. The model used to interpret the footprinting 
plots is derived in detail. Binding constants for 14 sites on the fragment are obtained simultaneously. It 
is important to take into account the effect of drug binding at  its various sites on the local concentration 
of probe elsewhere. It is also necessary to include in the model weak as well as strong Act-D sites on the 
carrier DNA which is present, since the carrier DNA controls the free-drug concentration. As expected, 
the strongest sites are those with the sequence (all sequences are 5’ - 3’) GC, with TGCT having the highest 
binding constant, 6.4 X lo6 M-l. Sites having the sequence GC preceded by G are weak binding sites, having 
binding constants approximately 1 order of magnitude lower than those of the strong sites. Also, the 
non-GC-containing sequences CCG and CCC bind Act-D with a binding constant comparable to those of 
the weak GGC sites. The analysis may reveal drug-induced structural changes on the DNA, which are 
discussed in terms of the mechanism of Act-D binding. 
Act inomycin D, Act-D (Figure I), is one of the most in- 
tensely studied anticancer drugs (Gale et al., 1981). Numerous 
investigations have shown that the agent exhibits its antitumor 
effects by binding to double-stranded DNA, thereby blocking 
transcription. The binding mechanism involves intercalation 
of the phenoxazone ring system of the drug via the minor 
groove of DNA at GC-rich sites (Gale et al., 1981). 
Footprinting studies on Act-D using DNase I (Lane et al., 
1983; Scamrov & Beabealashvilli, 1983; Fox & Waring, 1984) 
and Fe-MPE (van Dyke et al., 1982) showed that the highest 
‘We acknowledge the American Cancer Society, Grant NP-681, for 
supporting this research. 
affinity sites have the dinucleotide sequence 5’-GC-3’. Model 
building and a single-crystal X-ray structural analysis (Sobell 
1973) indicated that the specificity of Act-D for this sequence 
is due to hydrogen bonding between the 2-amino group of 
guanine of DNA and the threonine moiety located in the cyclic 
peptide of the drug. 
Although 5’-GC-3’ is the preferred binding site, there are 
other sites. The duplex d(CGTCGACG)*, which does not 
contain 5’-GC-3’, is able to strongly bind two actinomycin D 
molecules in a highly cooperative manner (Snyder et al., 1989). 
Further, in an effort to measure Act-D binding specificity, Rill 
et al. (1989) examined the DNA cleavage sites of the pho- 
toaffinity probe 7-azidoactinomycin D on several DNA re- 
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FIGURE 1: Structure of the drug actinomycin D. 
striction fragments and found that GC doublets were strongly 
preferred only if the 5’-flanking base was a pyrimidine and 
the 3‘-flanking base was not cytosine. In addition, the central 
GG doublet in the sequence TGGG is a strong Act-D site. 
We have shown that binding constants for drugs on random 
sequence DNA can be obtained by quantitative analysis of 
footprinting data (Dabrowiak & Goodisman, 1989; Rehfuss 
et al., 1990a,b; Dabrowiak et al., 1991). In the footprinting 
experiment, we measure the amounts of the various fragments 
produced by cleavage of a DNA polymer by a cleavage agent, 
the “probe”, in the presence of various amounts of the drug. 
The amount of fragment of a particular length is proportional 
to the amount of cleavage at a particular position on DNA. 
A plot of this quantity as a function of the amount of drug 
present, called the “footprinting plot”, reflects the ability of 
the drug molecule to inhibit (or, sometimes, enhance) cleavage 
by the probe. To analyze these “footprinting plots”, one must 
take into consideration overlapped drug sites, cleavage en- 
hancements, and the way in which the drug affects cutting by 
the probe. The analysis makes it possible to measure binding 
constants for overlapping sites and, if measurements are made 
at different temperatures, to obtain a full thermodynamic 
profile of a drug: AGO, AH’, and ASo (Dabrowiak et al., 
1990). 
The quantitative footprinting method is the only method 
capable of giving simultaneous values for a number of binding 
constants, corresponding to binding to different sites, and it 
is a valuable tool in investigating sequence specificity, selec- 
tivity, and wperativity in drug binding to DNA. Knowledge 
of these factors is important in the understanding of the 
mechanism of action of drugs and is crucial to drug design. 
In a previous report, we measured the binding constant of 
Act-D toward a small oligonucleotide duplex containing the 
sequence GCGC using DNase I footprinting (Rehfuss et al., 
1990a). In a preliminary study, we also analyzed the binding 
of actinomycin D to a 139-base-pair fragment of pBR 322 
DNA (Figure 2), using DNase I, Fe-MPE, and the cationic 
porphyrin Mn-T4 as footprinting cleavage probes (Ward et 
al., 1988; Rehfuss et al., 1990b). Our analysis focused on the 
initial loading events on the 139-mer, for drug concentrations 
from 0 to 7.64 pM, the upper limit corresponding to roughly 
50% occupation of the strong sites by drug. We derived 
equilibrium binding constants for the highest affinity sites and 
discussed the ability of different probes to reveal drug-induced 
structural changes on DNA. 
In this report, we derive binding constants for both the high- 
and low-affinity sites. We must ascertain whether the simple 
model used so far is sufficient to explain the footprinting results 
obtained for the complete range of actinomycin D concen- 
trations or whether additional assumptions (such as drug-in- 
d u d  structural effects) must be made. We show below that 
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FIGURE 2: The 139-base-pair fragment of pBR 322 DNA used in this 
study. Actinomycin D binding sites are indicated by rectangles, filled 
for strong sites and open for weak sites. Locations of the radiolabel: 
for the A-labeled experiment, position 33; for the G-labeled experiment, 
position 172. 
both high- and low-affinity sites on the carrier DNA must be 
included in the model, even if one is interested in calculating 
binding constants only for the high-affinity sites on the frag- 
ment. In addition, by considering drug concentrations lafge 
enough to produce a liigh degree of drug loading on the DNA 
fragment, we have an opportunity to detect drug-induced 
structural changes in DNA, which have been previously re- 
ported to occur for Act-D (Fox & Waring, 1984; Huang et 
al., 1988; Bishop et al., 1991). 
MATERIALS AND METHODS 
The HindIIIINciI, 139-base-pair restriction fragment from 
pBR 322 DNA was isolated, purified, and end-labeled for one 
set of experiments at position 33(A), and for a second set of 
experiments it was labeled at 172(G) with reverse transcriptase 
as previously described (Lown et al., 1986; Bromley et al., 
1986). Figure 2 shows the sequence of this fragment, as well 
as the drug-binding sites. The DNase I, obtained from Sigma 
Chemical Co., was used without purification. 
The DNase I footprinting experiments involving the 139-mer 
and Act-D were carried out as previously described (Ward et 
al., 1988). The photograph of the autoradiogram along with 
the drug concentrations (from 0 to 38.8 pM) used in the 
A-label experiment was published previously (Ward et al., 
1988). The experiments involving the G-labeled 139-mer were 
carried out under conditions identical to those of the A-labeled 
series except that only 10 drug concentrations were used, 
having final values in the reaction medium of 2.48, 3.40,4.86, 
6.93,9.89, 14.1,20.2, 28.8, 41.0, and 58.7 pM. The autora- 
diogram for the G-labeled experiment is shown in Figure 3. 
All experiments were carried out in buffer, containing 50 mM 
Tris-HC1,8 mM MgC12, and 2 mM CaC12, at  pH 7.5, for 10 
min. The final concentration of DNA in each of the reactions 
was 194 pM base pairs: 193 pM base pairs sonicated calf 
thymus DNA and - 1 pM base pairs radiolabeled fragment. 
Control reactions were carried out to determine the amount 
of enzyme necessary to leave -70% of the fragment uncleaved 
at the end of the digest time of 10 min (single-hit regime). 
The autoradiograms resulting from both the A- and G-labeled 
experiments were scanned with a microdensitometer/computer 
system to yield cross-sectional areas of bands, proportional to 
oligonucleotide concentrations (Dabrowiak et al., 1986). Plots 
of spot intensity as a function of drug concentration for each 
DNase I cleavage site (footprinting plots) were prepared in 
the manner previously described (Dabrowiak & Goodisman, 
1989). This involved using the “total-cut plot”, shown in 
Figure 4 for the A-label experiment, to correct the data for 
gel-loading errors and slightly different digest times. 
PLOTS 
Binding of Act-D to the 139-mer. It is known that acti- 
nomycin D binds to DNA via the minor groove, mainly at  
GC-rich sites (Gale et al., 1981). Our footprinting analysis 
confirmed that the strongest binding sites on the polymer were 
THEORY: MODEL FOR THE SYSTEM AND FOOTPRINTING 
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FIGURE 3: Autoradiogram for the G-labeled experiment. The Act-D 
micromolar concentrations are shown at the top of each lane. 
,0°1 
8 16 24 32 40 1501 I 8 t I I I ~ ~ ~ ~ ~ ~ ~ 1 ~ ~ ~ 1 1 ~ ~ 1 ~ i ~ ~ ~ ~ ~ 1 ’ ~ ~ ~ ~ ~ ~ 1  0 
[Actinomycin], pM 
FIGURE 4: Total-cut plot for the A-labeled experiment. The sum of 
the spot intensities corresponding to 93% of all cleavage products is 
plotted as a function of total drug concentration. The broken line 
is a least-squares fit to a linear function; the ratio of this function 
to the measured total cut multiplies all spot intensities for that drug 
concentration to correct for gel loading and other errors. 
5’-GC-3’, but the binding constant depended markedly on the 
bases on either side of the GC (Rehfuss et al., 1990b; Ward 
et al., 1988). In particular, sites having the sequence 5’- 
GGC-3’ were much weaker than other sites having the se- 
quence 5’-GC-3‘ (the 5’-GGC-3’ sites are considered among 
the weak sites in the present work). Furthermore, 5’-CCGT-3’, 
which does not contain the classical GC-binding sequence, 
appeared to be a binding site, with a binding constant com- 
parable to that of the GGC sites. 
The model used assumes that the drug bound to DNA 
blocks the probe from binding and cutting in a region near 
the position of the drug molecule. The actinomycin D molecule 
“covers” about 4 base pairs, including the G, the C, and one 
base pair on either side (Gale et al., 1981). Considering the 
size and shape of DNase I (Suck et al., 1988), we conclude 
that when an actinomycin molecule is bound at the GC site, 
DNase I cannot cleave at sites from about 3 base pairs on the 
3’ side of the GC to about 2 base pairs on the 5’ side. Thus, 
the inhibition region for a single drug molecule is about 7 base 
pairs in size; footprinting plots for all sites in such a region 
should be identical, within a multiplying constant. 
These footprinting plots show intensities monotonically 
decreasing with drug concentration. Footprinting plots for 
other sites show enhanced cutting, leveling off, and then further 
enhancement of cutting as drug concentration is increased; we 
assume that these are sites at which no drug binds. The 
explanation for the enhancement is given below. Other plots 
show initial increases of intensity with increased drug con- 
centration and a subsequent intensity decrease. These are the 
weaker binding sites, for which drug binds at a sufficiently 
high drug concentration, causing a decrease in intensity which 
overcomes the enhancement. At drug concentrations high 
enough to cause binding at the weak binding sites on the 
139-mer, weak-binding sites on the carrier DNA used in the 
experiment must also accept the drug. Thus, the analysis of 
footprinting data for higher drug concentrations requires 
modification in the model previously used for quantitative 
footprinting analysis of the initial loading events (strong 
binding sites), to include the activity of weak sites on the 
carrier DNA (Rehfuss et al., 1990b). 
The equilibrium between drug bound at drug-binding site 
i and free (unbound) drug is governed by the equilibrium 
constant Ki, according to 
where Si is the concentration of sites i (equal to the concen- 
tration of DNA polymers), Di is the concentration of polymers 
having drug bound at site i, and Do is the concentration of free 
(unbound) drug. For cutting sites within the ith drug-binding 
site, the probability that the probe can cut is thus determined 
by 
KiDo = ~ i / ( l  - vi) (2) 
where vi is the fraction of DNA polymers having a drug bound 
at drug-binding site i (and thus not cleavable at all sites in 
a 7-base-pair inhibition region centered near site i). Do is 
determined by equilibria like that given in eq 1 between free 
drug and drug bound to sites on the labeled DNA and the 
unlabeled calf thymus carrier DNA. Thus, the equation 
ct = 
KwDo 1 x KiDo +- KCDO + KCDO + + KwDo 139 ? i  + KiDo 
(3) 
to be solved for Do for each total drug concentration c,, by 
successive iteration. Here, c, and c, are the concentrations 
of strong and weak sites on the carrier, K, and K ,  are the 
respective binding constants, and the concentration of any site 
i on labeled fragment is the fragment concentration in base 
pairs, 1 X lo”, divided by the number of sites per fragment. 
Footprinting Studies on Actinomycin D 
If carrier is present in large excess, c, and c, are probably much 
larger than (1 X 104)/139, and equilibria with carrier dom- 
inate (eq 3). 
Modeling the carrier would not be necessary if it consisted, 
instead of calf thymus DNA, of unlabeled copies of the 
fragment studied. The theoretical analysis would be simplified 
(determination of c,, c,, K,, and K ,  would be unnecessary), 
but one would have to have larger amounts of the fragment 
and accurately determine its concentration. Most drug-DNA 
footprinting experiments to date have not used unlabeled 
fragment as the carrier. 
The probability of cutting at a site near i, if the drug-binding 
site is an isolated one, i.e., not overlapped with other drug sites, 
is proportional to 1 - vi, which is equal to (1 + KiD0)-l. If 
the cleavage site is near two drug sites, j and k, so that drug 
bound at either site will inhibit cleavage by DNase I, 1 - vi 
is equal to [(l + Kpo)( 1 + KkDO)]-l. This assumes that drug 
binds independently at the two sites j and k. If the sites are 
close enough together so that a drug molecule bound at one 
prevents drug from binding at the other but that a drug bound 
at either one prevents cutting at site i ,  (1 - vi) is replaced by 
(1 + KjDo + &Do)-'. Such anticooperative binding occurs 
for the strong sites (GC's) at 101-102 and 103-104 of the 
139-mer (Figure 2). 
Enhancements in Cleavage Rate. The amount of cutting 
at site i ,  in addition to being proportional to (1 - vi) ,  is pro- 
portional to the local concentration of DNase I. If the amount 
of DNase I bound to the polymer is small and remains constant 
as drug is added, the binding of drug at its binding sites must 
redistribute the enzyme to sites where no drug is bound, leading 
to enhanced cutting. Evidence for this is the constancy of 
"total cut" with drug concentration, the total cut being the sum 
of the measured intensities, corresponding to 93% of all 
fragments produced by cleavage (see Figure 4). The local 
concentration of enzyme, and hence the cutting rate, at a site 
where no drug is bound is inversely proportional to the fraction 
of the sites on the DNA polymer which are not blocked by 
drug (Ward et al., 1988). To take this into account, the local 
concentration of probe, the factor (1 - vi) ,  is multiplied by (1 
- Kecb)-l, where K, is the enhancement constant and cb is the 
total concentration of drug bound on the fragment. The value 
of K, can be estimated from the fraction of the sites on the 
DNA polymer which are binding sites, but we generally allow 
its value to be determined by the minimization of D (see 
below). 
Of course, the number of DNase I molecules bound to the 
fragment cannot remain constant for indefinitely large con- 
centrations of bound drug; eventually, enough drug will be 
bound to remove probe molecules from the fragment. 
Therefore, the enhancement factor should behave as (1 - 
KeCb)-' only for small cb, but it should increase less rapidly for 
large cb, never becoming infinite. It can be shown (Goodisman 
& Dabrowiak, 1992) for a simplified situation that the en- 
hancement factor behaves like (1 - Kecb)-' for small cb and 
remains ftnite even when all sites are blocked. Since (1 + K&b) 
behaves like (1 - KeCb)-l for small cb but increases less rapidly 
for larger cb,  one might use (1 + Kecb) as the enhancement 
factor. In the example studied (Goodisman & Dabrowiak, 
1992), it is found to work less well than (1- KeCb)-l, but the 
truncated power series C;=o(K,cb)' are found to work better. 
Spot Intensities. The intensity of the spot on the autora- 
diogram due to a fragment produced by cutting at site i, when 
the drug concentration is c,, is 
T i ( C , )  = ki(l - vi)(1 - KeCb)-l (4) 
The tilde refers to a theoretical value; Ii(ct) is the measured 
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FIGURE 5 :  Total-cut plot for the G-labeled experiment. See caption 
for Figure 4. 
intensity. In the expression for li, ki includes a cutting rate 
constant and various proportionality constants, and it is in- 
dependent of c,. For a site which cannot be blocked by drug 
binding (enhancement site), l i (c,)  = ki(l - Kecb)-l. 
The theoretical intensities j i (ct)  can now be calculated in 
terms of the various parameters: binding constants Ki, en- 
hancement constant K,, and carrier properties c,, c,, K,, and 
K,. We determine the values of these parameters by mini- 
mizing the mean-square deviation 
D = C[Ii(ctj) - Ti(ctj)12 ( 5 )  
ij 
Here, cti is thejth total drug concentration. The minimization 
is performed using the Simplex search technique (Fletcher, 
1980). 
The totals of the cut-fragment intensities for the A-label 
gel (26 values, corresponding to total drug concentrations from 
0 to 38.8 pM), plotted in Figure 4, were fitted to a constant 
term, to a linear function, and to a quadratic function of drug 
concentration c,. Since the linear and quadratic functions gave 
no significant improvement in the fit, total cleavage on the 
139-mer is essentially constant with added Act-D, justifying 
our use of the enhancement model discussed above. The linear 
function 247.1 - 0 . 8 2 5 ~ ~  (dashed line in Figure 4) was used 
to smooth the intensities in the individual footprinting plots 
(correcting for errors in loading DNA into the gel, etc.) by 
multiplying all I&J for a given c, by (247.1 - 0.825cJ/C,Zi(ct). 
The total-cut results for the G-label gel, shown in Figure 5 ,  
were treated similarly. The linear fit, J(c,) = 1627.1 - 8.29ct, 
was used to smooth intensities for this gel in the way this was 
done for the A-label gel, by multiplying all Zj(ct) by J(c,)/ 
For the A-label gel, we rejected data from sites weakly 
cleaved by DNase I, retaining data for 54 sites. For the 
G-label gel, data for 43 sites were retained. Some of the 
footprinting plots used in the analysis for the A-label gel are 
shown in Figure 6 (after total-cut correction). 
In our previous work (Rehfuss et al., 1990b), we considered 
only the strong binding events, using footprinting plots for the 
following sites: 54-56, 60, 62-69, 71-72, 85, 87, 98-99, 
145, and 161. Because the position of the bands is not linear 
in site number and because there is not a spot for each band, 
assignment of the bands to sites is problematic, especially for 
sites above 110, corresponding to larger DNA oligomers, 
because resolution decreases. However, the G-labeled frag- 
ment, which has the 32P atom on the opposite strand and at 
the opposite end of the 139-mer from the A-labeled fragment 
(Figure 2), gives a gel for which site resolution is best for the 
higher numbered sites, which now correspond to smaller oli- 
Cizi(4* 
102-103, 106, 112, 114, 120, 124, 128, 133, 136, 138, 143, 
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Footprinting Studies on Actinomycin D 
gomers. Comparing the gels from the A-labeled and the 
G-labeled fragment facilitates indexing of these bands. The 
numbering used previously is apparently low by several site 
numbers for sites above about 120. 
To identify strong binding sites, we found it useful to cal- 
culate the initial slopes of the footprinting plots (fragment 
intensities vs total drug concentration) and divide the slopes 
by the intercepts (intensities for zero drug concentration) to 
get “initial relative slopes” (Ward et al., 1988). Stronger 
binding sites are easily identified by negative slopes, while 
positive slopes characterize weaker or nonbinding (enhance- 
ment) sites. The constancy of initial relative slopes over en- 
hancement sites provides further evidence for the validity of 
the redistribution-enhancement model (Ward et al., 1988). 
Deviations from constancy may indicate drug-induced struc- 
tural changes in DNA, manifesting themselves in a change 
in cleavage rate constant at the site (Rehfuss et al., 1990b). 
In the previous analysis (Rehfuss et al., 1990b), sites were 
classified as either enhancement or binding sites. Some of the 
sites considered as enhancements at that stage (for example, 
85,87, 112, 114) are revealed to be influenced by weak-binding 
drug sites when results for drug concentrations greater than 
7.64 pM are considered. For lower drug concentrations, 
however, they behave like typical enhancements, as can be seen 
from the goodness of fit by the theoretical enhancementsite 
curves (dashed lines in Figure 6). Clearly, examination of 
initial relative slopes is not useful when one considers weaker 
sites, since intensities for such sites show an initial enhancement 
(followed by a decrease in intensity as c, increases further. It 
is necessary to consider the entire footprinting plot in order 
to classify a site as binding or enhancement. 
Role of Carrier DNA. Since appreciable binding to the 
weaker sites takes place only at higher drug concentrations, 
we modeled the carrier in our previous work (Rehfuss et al., 
1990b) as consisting of only one kind of site, with concentration 
c, and binding constant K,, K, representing the average of the 
strong binding sites on the carrier. We carried out the min- 
imization of D using several different values of c,, and we found 
that the minimum value of D was lowest near c, = 4.7 p M .  
The enhancement factor was written as (1 - Kecb)-’, where 
cb is the concentration of drug bound to fragment. The value 
found for the enhancement constant K,  was 4.9 X lo6 M-l. 
K, should be equal to the reciprocal of the concentration of 
drug-binding sites on the fragment. Since the fragment is 139 
base pairs long and each site occupies 7 base pairs, there are 
20 sites per fragment; multiplying by the fragment concen- 
tration of 1/139 pM should make K, about 20/139 pM-* = 
7 x lo6 M-l.  
With 19 drug concentrations and 32 sites, the calculation 
of the deviation D involved 608 data points. The lowest value 
of D (Rehfuss et al., 1990b) was 126, making the root- 
mean-square deviation d126/608 = 0.46, about the same as 
the error in the data points, as judged by their scatter. 
However, certain footprinting plots were noticeably less well 
fitted than others, indicating inadequacies in the model. The 
low-concentration part of the G-label gel was analyzed sim- 
ilarly to the A-label gel. The determined binding constants 
for strong sites were in agreement with those from the A-label 
gel. 
In the present calculations, designed to determine weak- and 
strong-site binding constants, we consider footprinting plots 
from the A-label gel for all sites for which appreciable in- 
tensities are available. We develop the model used to interpret 
the A-label gel below, and we derive the strong-site and 
weak-site binding constants. Then, the model is used to in- 
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terpret footprinting plots from the G-label gel which have 
appreciable intensities and to obtain binding constants. Al- 
though the data from the G-label gel show a lot of scatter, its 
autoradiogram has the best site resolution for the higher 
numbered sites, as mentioned above. By comparing the plots 
derived from the G-label gel with those obtained from the 
A-label gel to check on site numbering, we conclude that the 
A-label site numbers are too low by about 3 for sites after 
about 120. The original reference numbering is used in the 
present paper. 
Since we are now dealing with the full range of drug con- 
centrations (to 38.8 p M ) ,  we must include the additional 
parameters c, and K,, representing the concentration and 
average binding constant of weak sites on carrier DNA. ”e 
enter the determination of the freedrug concentration Do. We 
use a value of 5 pM, as found in earlier calculations (Rehfuss 
et al., 1990b), for the concentration of strong sites on carrier 
and (initially) 13 pM for the weak-site concentration c, since, 
on the fragment, there are about 2l/* as many weak sites as 
strong ones. We determine the value of K ,  in the mini- 
mization, along with the strong-site binding constant K,, the 
enhancement constant K,, and the site-binding constants for 
the fragment. 
ANALYSIS: DEVELOPMENT OF THE MODEL 
We now discuss the development of the model as it applies 
to the A-label gel data. We are able to use data for 54 sites, 
and there are 26 drug concentrations, giving 1404 data points 
to be fit. Table I summarizes the behaviors of the 54 foot- 
printing plots used (uncorrected site numbers are given), and 
it gives the assumptions of the model used to explain them. 
To limit the number of parameters, several unknown weak 
binding sites have been assigned the same binding constant, 
K,, although one might consider assigning them different weak 
binding constants, and K9 has been used to describe the binding 
to the sequence CCC at 129-131, even though this binding 
constant need not be the same as that for the sequence CCGT 
at 123-1 26. 
The two GC sites at 101-102 and 103-104 are so close 
together that binding of drug at one excludes binding at the 
other. This exclusion explains why the intensity for cutting 
at site 98 (Figure 4) never decreases to zero (cutting here is 
blocked by drug binding at 101-102, which is in turn blocked 
by drug binding at 103-104) and why the intensities for sites 
99, 102, and 103 decrease more sharply with drug concen- 
tration than the intensity for site 106 (they are affected by 
binding at either GC site). An attempt to include a similar 
kind of exclusion between other nearby weak binding sites (e.g., 
the GGC at 119-121 and the CCG at 123-126) failed: D 
increased when the exclusion-binding model was used for sites 
in this region. Presumably, drugs bound at these two positions 
are not close enough to interfere with each other. We also 
tried to put in a second binding constant for the weak sites 
in the region 160-165, which is 5’-GCCG-3’, but minimization 
of D returned a very small value for this binding constant. This 
means that 5’-CG-3’ is so much weaker than 5’-GC-3’ as a 
binding site that binding to the former site can be neglected. 
Weak Act-D Sites on Carrier DNA. With the carrier-site 
concentrations given above, and an enhancement factor of (1- 
Kgb)-’, we minimize the sum of the squared deviations D with 
respect to K, and the binding constants on fragment and 
carrier. This represents a total of 16 nonlinear parameters. 
The binding constants obtained, with c, and c, fixed respec- 
tively at 5 and 13 pM, are given in column I of Table 11. The 
logarithms of the fragment binding constants K,-K13 are given, 
followed by the logarithms of the carrier binding constants K, 
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carrier, as is shown by carrying out the minimization of D with 
c, reduced from 13 to 0.05 pM (essentially zero). The 
fragment binding constants are all reduced, as shown in column 
11. (Of course, the value of K,  must increase markedly when 
the value of c, is reduced markedly.) With a low or zero value 
of c,, the maximum concentration of drug that can be bound 
to the carrier is 5 pM (the value of cc), so that when the total 
drug concentration exceeds 5 pM, the free-drug concentration 
rises rapidly with total drug concentration and smaller frag- 
ment binding constants are required to explain the measured 
binding isotherms. Since D for the low value of c, (calculation 
11) is much larger than for c, = 13 pM (627 vs 517), we have 
to accept an appreciable value of c, as correct, with the higher 
binding constants that result. 
To ascertain whether the value of c, can be determined from 
the minimization of D and, if it can, what the value of c, is, 
we performed minimizations of D assuming c, = 10 and 7 pM. 
The results are shown in columns I11 and IV of Table 11. The 
values of D from columns I, 111, and IV show a shallow 
minimum as a function of c,. Fitting them to a parabola, we 
find the minimum at c, = 10.3 pM, with D = 507. In all 
subsequent calculations, we maintain c, at 10 pM. It may 
be noted that increasing c, leads in general to increases in 
fragment binding constants, but that the changes when c, 
varies from 7 to 13 pM are small. The binding constant K ,  
must of course decrease with increased c,, while K,  hardly 
changes with c,. 
Enhancement Factor. As mentioned above, the enhance- 
ment factor (1 - Kecb)-l cannot be correct for large values of 
Cb, since this factor becomes infinite for cb = l / K e ,  whereas 
the enhancement should never become infinite (Goodisman 
& Dabrowiak, 1992). When (1 + Kecb), which behaves like 
(1 - Kecb)-l for small cb and remains finite for all values of 
cb, was used for the enhancement factor, the results of column 
V of the table were obtained. The resulting binding constants 
differ only slightly from those of column 111, but D is much 
larger (554 instead of 507), so that the factor (1 - Kecb)-' fits 
our data better, and this form of the enhancement is used in 
succeeding calculations. 
The lowest value of D so far is from calculation 111, D = 
507. The root-mean-square deviation is v'[507/(26 X 54)] 
= 0.60, which is somewhat greater than our estimate for the 
precision of the experimental intensities. Thus, we cannot state 
that our model fits the data to within experimental error. This 
implies that some effects are not yet included in our model, 
Table I: Behavior of Footprinting Plots and Their Interpretation 
from the A-Label Gel" 
behavior 
site of spot 
no.b intensities interpretation 
54, 55 
56-59 
62-66 
67 
68-69 
71-72 
75-78 
79 
80 
81, 83 
85, 87 
89, 90 
92, 94 
95 
96 
98 
99, 102 
103 
106 
108 
112 
114 
120 
124 
126 
128 
133, 136 
138 
143, 145 
147 
150 
154 
158. 161 
inc with c, 
rap. inc with ct 
rap. dec 
very rap. dec 
rap. dec 
rap. dec 
inc, then dec 
inc, then dec 
unchanged with 
c,, then dec 
inc, then dec 
slowly inc 
inc 
inc 
slowly inc 
inc 
dec with ct 
rap. dec with ct 
rap. dec 
rap. dec 
inc 
inc, then dec 
inc, then dec 
unchanged with 
ctr then dec 
inc, then dec 
rap. inc 
inc, then dec 
dec with ct 
dec with c, 
inc, then dec 
inc, then dec 
inc 
inc, then dec 
inc. then dec 
very weak bind., K7 
enh 
bind. to G C  at 63-64; K ,  
bind. to GC's at 63-64 and 69-70, K2 
bind. to G C  at 69-70, K2 
bind. to G C  at 69-70 
bind. to G G C  a t  76-78, K ,  
bind. to  76-78 and CCG a t  80-82, K4 
bind. to C C G  a t  80-82, K4 
bind. to CCG a t  80-82 
unknown weak bind. site, K4 
enh 
enh 
enh 
enh 
bind. to G C  at 101-102, K5 
bind. to G C  at 101-102 or 103-104, K6 
bind. to G C  at 101-102 or 103-104 
bind. to G C  a t  103-104, K6 
enh 
bind. to nonclassical site, K7 
bind. to G G C  a t  119-121, K8 
bind. to CCGT at 123-126, K9 
bind. to CCGT a t  123-126 
enh 
bind. to C C C  a t  129-131, K9 
bind. to G C  at 137-138, K l o  
bind. to G C  a t  137-138 
bind. to G G C  a t  143-145, K l l  
bind. to G G C  a t  149-151, K I 2  
enh 
bind. to G C  a t  160-161, K 1 3  
bind. to GCCGG at 160-164. K 1 2  
a Abbreviations: rap., rapid; inc, increase; dec, decrease; bind., 
binding; enh, enhancement. bSite numbers refer to the squence  shown 
in Figure 2. Numbers greater than -110 are probably low by -3. 
CAll sequences are  5' to 3'. 
and K ,  (for strong and weak sites), the value of the en- 
hancement constant K, in the factor ( I  - Kecb)-l, and the value 
of D. 
All of the binding constants for strong sites on the fragment 
are significantly higher than the corresponding binding con- 
stants determined previously (Rehfuss et al., 1990b). The 
reason for this is the inclusion of weak binding sites on the 
Table 11: Effect on Calculated Binding Constants of Weak-Site Concentration on Carrier and Expression Used for Enhancement 
calculation 
log of I I1 111 IV V 
binding c,, = 13 p M ,  c, = 0.05 pM, c, = 10 pM, c, = 7 p M ,  c, = 10 pM, 
constant (1 - KeCb)-I (1 - Kecb)-I (1 - KeCb)-' (1 - KeCb)-' ( l  + K&b) 
K ,  6.37 5.60 6.15 6.31 6.16 
K2 6.01 5.48 6.07 6.01 6.07 
K3 5.17 4.88 5.15 5.09 5.11 
K4 5.13 4.92 5.18 5.06 5.12 
KS 6.05 5.83 6.15 6.01 6.05 
K6 5.95 5.65 5.96 5.82 5.97 
Kl 4.31 4.23 4.41 4.33 4.08 
K8 4.97 4.87 4.95 4.94 4.85 
K9 5.23 5.01 5.19 5.16 5.20 
KI, 6.61 6.01 6.60 6.56 6.68 
K ,  1 5.35 5.00 5.29 5.19 5.26 
Kl2 4.40 4.42 4.47 4.51 4.35 
K ,  3 5.55 5.16 5.46 5.39 5.43 
Kc 7.13 6.89 7.21 7.01 6.92 
K ,  5.78 7.10 5.93 6.20 6.12 
Ke 7.9 x 106 8.2 X lo6 8.2 X lo6 8.0 X lo6 1.58 x 107 
D 517 627 507 522 554 
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Table 111: Effect on Calculated Binding Constants of Inclusion of 
Cooperative Binding and Changed Enhancement Expression 
~ 
calculation 
I I1 I11 
log of c, = 10 pM, c, = 10 pM, C, = 10 pM, 
binding (1 - KcCb)-I, (1 - K.&b)-I, C:%dKeCb)', 
constant 17 parameters cooperativity cooperativity 
Kl 6.17 6.16 6.16 
K2 5.94 5.90 5.87 
K3 5.14 5.00 4.95 
K4 5.16 5.10 4.89 
K5 6.23 6.07 6.01 
K6 6.13 5.90 5.92 
K7 4.33 4.14 4.17 
K8 4.94 4.8 1 4.71 
K9 5.10 4.95 4.89 
KlO 6.63 6.48 6.43 
KI I 5.25 5.05 5.02 
K12 4.45 4.33 4.30 
K13 5.46 5.27 5.24 
4 4 5.65 5.31 5.60 
Kc 7.28 7.26 7.03 
KW 5.92 5.82 5.61 
value of K ,  7.2 X lo6 7.2 X lo6 7.1 X lo6 
D 495 477 435 
Parameters in 
tanh Factor 
*I  1 .71 1.70 
0 2  5.0 X lo7 4.0 X lo8 
0 3  6.9 X 10" 5.9 X 
for example structural changes. Sites for which the fit of 
theoretical to experimental footprinting plots is worst at this 
stage are 78, 87, 112, 128, and 147. 
The solution to the problem for site 128 has already been 
noted: cutting at this site is inhibited by drug binding at the 
CCC sequence located at base pairs 129 to 131, and the drug 
binding constant for this sequence may be different from K9, 
which describes drug binding to the CCG sequence located 
at 123-125. By including an additional constant K,, to de- 
scribe drug binding to the CCC, we minimize D with respect 
to 17 nonlinear parameters, obtaining the results in column 
I of Table 111. We note a reasonable improvement in D, from 
507 to 495, when the additional parameter is inserted; values 
of other parameters are not changed much. 
Increased Binding. Comparison between theory and ex- 
periment shows that, in general, the footprinting plots calcu- 
lated from our model for binding sites do not decrease sharply 
enough with total drug concentration for concentrations near 
20 pM. Correspondingly, footprinting plots calculated for 
enhancement sites do not increase sharply enough in this re- 
gion. Apparently, there is a rather rapid increase in the 
concentration of drug bound to the weak sites on the fragment 
when the total drug concentration increases past 20 pM. 
(Because intensities for cutting at sites blocked by drug binding 
at strong sites are already near zero at this point, no infor- 
mation is available about the amount of drug bound to strong 
sites.) This could be due to a structural change in the fragment 
induced by the bound drug or to cooperative binding. It may 
be noted that there is a sudden (although relatively small in 
magnitude) drop in total cut (Figure 4) after [Act-D] = 20 
pM. This affects the correction factors used in the total-cut 
smoothing, but this cannot cause both sharp increases and 
sharp decreases in individual footprinting plots; these are 
present in the unsmoothed plots. 
We model the increase in the effective drug binding constant 
by multiplying each binding constant Ki ( i  = 1-14) by the 
same function of bound drug concentration: 
Kieff = Kj(al + (ai - 1) tanh [az(cb-a3)]) ( 6 )  
3.2 1 
FIGURE 7: Increased binding factor, K t f f / K i  (eq 6), which multiplies 
binding constants to give effective binding constants, as a function 
of the bound drug concentration. Optimum (minimum 0) values of 
the parameters are used. 
According to the above function, the effective binding constant 
is Ki in the absence of bound drug, when cb, the calculated 
concentration of drug bound to the fragment, is much less than 
a3. It becomes (2a1 - l)Ki when cb is much greater than u3, 
the parameter a2 giving the sharpness of the change. With 
eq 6 ,  three new parameters are introduced, making the total 
number 20. As shown in column I1 of Table 111, there is a 
small but significant improvement in the fit. 
The enhancement factor for binding (eq 6 )  is plotted as a 
function of cb in Figure 7, using the best values of the pa- 
rameters a l ,  u2 and a3. For the five highest total drug con- 
centrations (20.3, 23.8, 28.0, 33.0, and 38.8 pM), cb is cal- 
culated as 0.059, 0.075,0.080,0.084, and 0.087 pM, respec- 
tively. Then, the enhancement in binding occurs mostly be- 
tween total drug concentrations of 20 and 24 pM, which is 
where the sharp intensity decreases occur. In fact, D is found 
to be insensitive to the value of a2. This is because we know 
only that most of the increase in drug binding (by a factor of 
2.4) occurs between 20 and 24 pM, so that a2(24-20) pM must 
be much larger than unity, and a2 >> 2.5 X IO5 M-I. 
On studying the observed and calculated footprinting plots, 
we observe one remaining problem: calculated plots for en- 
hancement sites show intensities which rise sharply with total 
drug even for the highest drug concentrations, whereas the 
experimental intensities apparently level off. This is related 
to the fact mentioned above that (1 - Kecb)-I, which becomes 
infinite for cb = l/Ke, cannot be the correct enhancement 
factor for large cb, but only for small cb. Functions behaving 
like (1 - Kecb)-l for small cb but increasing less for large cb 
are the power series' c&o(Kecb)-l for finite values of n. The 
linear function (n = 1 )  has already been tried and found 
unsatisfactory (column V, Table I). After some experimen- 
tation, we chose n = 10, although the exact value of n is not 
critical; the results, which include a significant decrease in D 
from n = 0, corresponding to (1 - & , ) - ' ,  are given in column 
I11 in Table 111. 
D is reduced to 435 and the root-mean-square deviation is 
now v'[435/(54 X 26)], or 0.56. The footprinting plots now 
seem to reproduce the experimental ones quite well, with a 
few exceptions (see Figure 6 ) .  To improve our model by 
increasing the number of variable parameters would be un- 
justified and would require more work, with probably little 
decrease in D. The three parameters in eq 6 already have little 
chemical basis except that they produce the increased binding 
shown by the data. Note that the various improvements in 
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position" sequence A-label gel G-label gel 
62-65 TGCT 35.0 4.8 
68-71 CGCA 18.0 
76-79 GGCA 2.1 1.3 
80-83 CCGT 1.8 1.7 
100-103 TGCG 25.0 22.0 
102-105 CGCT 20.0 8.8 
various various 0.3 
118-121 CGGC 1.2 0.3 
123-126 CCGT 1.8 0.9 
128-1 3 1 ACCC 9.4 4.8 
136-139 TGCT 64.0 30.0 
143-1 46 GGCA 2.5 2.0 
149-152 GGCT 0.5 0.8 
159-162 TGCC 4.2 4.5 
"Site numbers refer to the sequence in Figure 2. 
Table V: Behavior of Footprinting Plots and Their Interpretation from the 
G-Label Gel" 
behavior 
of spot 
site no.b intensities interpretation 
47, 49, 56 inc with ct enh 
65 rap. dec strong bind. to GC at 63-64; K,' 
75 inc, then dec bind. to GGC at 76-78, K,' 
82, 84 level, then dec weak bind. site, K i  
93,95 inc enh 
101 rap. dec with ct 
105 rap. dec 
110 inc with c, enh 
119 inc, then dec bind. to GGC at 119-121, Kd 
122 inc, then dec bind. to GGC at 119-121 
123-126 inc, then dec bind. to CCGT at 123-126, K,' 
127, 128 inc, then dec 
130-132 inc, then dec bind. to CCC at 129-131, K,' 
134, 135 dec with ct bind. to CCC at 129-131 
136-141 dec with ct bind. to GC at 137-138, K{ 
142 inc, then dec bind. to GGC at 143-145, KId 
144, 146 inc, then dec bind. to GGC at 143-145, K I d  
148 bind. to GGC's at 143-145, 149-151 
149-150 bind. to GGC at 149-151, KI1' 
152, 153 bind. to GGC at 149-151 
154 inc with c, enh 
158 inc, then dec bind. to GCCGG at 160-161, K , {  
"Abbreviations: rap., rapid; inc, increase; dec, decrease; bind., binding; enh, 
enhancement. bSite numbers refer to the sequence shown in Figure 2. CAll 
sequences are 5' to 3'. 
bind. to GC at 101-102, K i  
bind. to GC at 101-102 or 103-104, K{ 
bind. to above and CCC, 129-1 3 1 
level, then dec with ct 
level, then dec with ct 
level, then dec with ct 
901 
801 
3 701 
3 SO: 
0 -  
O / / '  
' 
/ 
/ 
/ 
0 
* 
--. - - _  
our model, while lowering D significantly, have had little effect 
on the calculated values of the binding constants for fragment 
sites. Thus, further changes in our model will probably not 
change the ICs much. The binding constants for our best 
calculation (lowest D) are given in Table IV. 
Footprinting with G-Labeled 139-mer. We now consider 
the data from the G-label gel, analyzing it by the model de- 
veloped for analysis of the A-label gel. This means that we 
use the same values for the concentrations of strong and weak 
sites on the carrier rather than determine the best values for 
these concentrations by minimization of the mean-square 
deviation D. For the enhancement factor, we use ~ , !~o(Ke~b) - l ,  
and no correction for cooperative binding is included. 
Intensities for nine actinomycin concentrations (2.4, 3.4,4.9, 
6.9, 9.9, 14.1, 20.2, 28.7, and 40.9 pM) plus two controls were 
used. Having two sets of intensities for zero drug concentration 
allows an assessment of the error in the intensities. In general, 
the data from the G-label gel show more scatter than those 
from the A-label gel. This is evident in the plot of total cut 
vs drug concentration (Figure 5 ) .  The linear fit to the total-cut 
plot, 1627.1-8.29ct, was used to smooth intensities, as discussed 
above for the A-label gel. There appears to be a drop-off in 
the total cut at a drug concentration of 20-24 pM, as in the 
A-label gel. Several footprinting plots are shown in Figure 
8. The scatter in the data should be noted, as well as the 
9 
* 
0" I I I I I ?  I I I I I I I .  I I .  I I I I I I I I I I I I b I I I ,P 6 12 18 24 30 30 42 48 5 4  d0 
[Actinomycin], PLY 
FIGURE 8: Footprinting plots from the G-label gel, after total-cut 
smoothing. Symbols are measured spot intensities; broken curves are 
fits calculated from the model. In the top plot, *, 0 ,  and 0 are for 
sites 84, 101, and 110; in the middle plot, *, 0 ,  and 0 are for sites 
122, 127, and 135; in the bottom plot, *, 0 ,  and 0 are for sites 138, 
148, and 154. 
apparent large changes in intensities for some sites near 20 
pM drug concentration. 
We used data for all sites for which intensities were ap- 
preciable and the fluctuations were significantly smaller than 
the intensities themselves. This means that 43 sites were 
considered, as listed in Table V, and 473 total data points. 
Table V indicates how each footprint was modeled. Note that 
the Ki' for this gel do not always correspond to the Ki for the 
A-label gel. 
There are a total of 15 parameters in this model: 12 binding 
constants on the fragment, the strong- and weak-site binding 
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of concentration c, and binding constant K,. This leads to 
eq 3. 
By solving all the equilibrium equations simultaneously, we 
determined ci for each site i and for each c,. For any cleavage 
site within the inhibition region of drug site i, the probability 
that cleavage can occur is the probability that no drug is bound 
at site i, 1 - ci/c. Some cleavage sites may be blocked by two 
independent drug-binding events; if the drug sites are j and 
k, the probability of cleavage is (1 - c,/c)(l - c k / c ) .  
In addition, we noted that if bound drug prevents cleavage 
at some sites on a fragment by blocking access of the enzyme 
to part of the DNA, the concentration of enzyme at other 
places on that fragment, where no drug is bound, should in- 
crease. Thus, the cleavage rate, which is proportional to the 
local concentration of enzyme, should increase at those places. 
This is the origin of the enhancement factor, which multiplies 
all intensities. The factor was written as E = (1 - &&)-I, 
where K, is a constant and cb is the concentration of drug 
bound to fragment, or as a finite power series, &,(K,Cb)', 
Finally, at total drug concentrations high enough for appre- 
ciable binding to the weak sites, we noted an abrupt decrease 
in amounts of cleavage products with drug concentration. This 
is modeled by multiplying all binding constants by an in- 
creasing function of cb (eq 6). The values of the parameters 
in this function are determined, along with the binding con- 
stants to 139-mer and carrier and the enhancement constant 
K,, by variation. 
We found the set of values of the parameters which mini- 
mized the sum of the squared deviations between calculated 
and experimental intensities: 
D = C(li(ctj) - zLct,)I2 (9) 
Here, Zl(ct,) is the measured intensity or amount of fragment 
resulting from cleavage at enzyme site i when the total drug 
concentration is ct, and Ti(ct,) is the corresponding intensity 
calculated from our model. The measured cut-fragment in- 
tensity is proportional to the probability of cleavage. For the 
A-label gel, there were 54 footprinting plots, each corre- 
sponding to a particular cleavage product, and 26 drug con- 
centrations, giving 1404 points. Our best calculation involved 
20 nonlinear parameters and led to D = 435. The root- 
mean-square deviation was the same size as the fluctuations 
in measured intensities from point to point. 
DISCUSSION 
In this article, we present measured footprinting plots for 
actinomycin D binding to DNA, as well as the model and 
analysis which allow us to derive binding constants for strong 
and weak sites, as well as other parameters. This is the only 
quantitative footprinting study of which we are aware which 
deals simultaneously with such a large number of footprinting 
plots and such a large number of ligand concentrations. The 
model involves the same assumptions as did models used in 
previous work (Ward et al., 1988; Rehfuss et al., 1990b), but 
modifications were necessary to take into account the behaviors 
of the footprinting plots revealed at high drug concentrations. 
The footprinting plots f,(c,,) calculated from our model re- 
produce the behavior of the observed footprints quite well in 
general (see Figure 6 ) .  A measure of the experimental error 
or scatter in the intensities is obtained from deviations from 
the expected continuous variation of intensity with drug con- 
centration, as estimated by fitting a line through several points, 
and is about 0.5 unit. 
However, there are exceptions, identified by inspection of 
the footprinting plots, examples of which are shown in Figure 
6,  or by calculation of the contribution of each site to D sites 
i ,  
constants on the carrier, and the enhancement constant K,. 
Minimization of D with respect to these parameters gives a 
value of 1.03 X lo4. Dividing by 473 and taking the dquare 
root gives a meari-square deviation of 4.7, which seems slightly 
bigger than the fluctuations in the data points. The carrier 
binding constants were found to be 89.3 X IO5 and 8.9 X lo5 
M-' for the strong and weak carrier sites, and the enhancement 
constant was 7.7 ,X lo6 M-l. 
The values of the fragment binding constants are given in 
Table IV. Note that, for this gel, resolution is low and site 
numbering is uncertain for the lower numbered sites. This 
probably accounts for the constant for the first site being much 
lower than that calculated from the A-label gel: spots for the 
single-site 65 considered to be responding to binding to the 
GG at 63-64 were actually superpositions of spots arising from 
cutting at several sites. Thus, the value of this binding constant 
is very poorly determined from the G-label gel. Similarly, the 
constants for the overlapped sites having GC's at 101-102 and 
103-104 were determined from data from only two foot- 
printing plots, as compared to five on the A-label gel, so one 
cannot put much confidence in the smaller value. On the other 
hand, the value found for the binding constant for the site 
having GC at 137-138 is probably more reliable from the 
G-label than from the A-label gel because six footprinting plots 
were used in the former case and only three were used in the 
latter. 
Summary. It was assumed that when a molecule of acti- 
nomycin D is bound to DNA, it blocks about 7 base pairs from 
cleavage by the probe DNase I. The size of the inhibition 
region follows from the structures of the drug and probe as 
well as from previous footprinting work on this system. In 
setting up our model, we must decide which drug-binding 
events, if any, affect cleavage at  each site for which we have 
a footprinting plot. A consistent picture could only be made 
if the numbering of the footprints for the A-label gel was 
urlderstood to be too low by about 3 base pairs for sites after 
about 110, where the numbering for the A-label gel becomes 
uncertain. That the original numbering was incorrect in this 
way was confirmed by observation of footprinting data ob- 
tained from G-labeled fragment, for which assignment was 
more accurate for the higher numbered sites. 
The binding of drug to a site on DNA is governed by the 
simple chemical equilibrium 
(7) 
where Ki is the binding constant (whose value our analysis 
attempts to derive), ci is the concentration of fragments which 
have drug bound at site i, c is the total concentration of 
fragments (so c - ci is the concentration of fragments having 
no drug bound at site i ) ,  and Do is the concentration of free 
or unbound drug. Where two strong binding sites are adjacent, 
drug binding at one prevents drug binding at another and eq 
7 must be modified. The free-drug concentration is related 
to the known total drug concentration c, by 
Ct = Do + cb + C, (8) 
where cb is the concentration of drug bound to the fragment 
(cb = C,ci) and c, is the concentration of drug bound to sites 
on the carrier DNA. The value of c,,, which was expected 
to be much larger than cb because there was about 200 times 
more carrier than labeled fragment, was determined by 
equilibria like that in eq 7. For simplicity, we assumed that 
carrier sites could be represented by two kinds: strong sites 
of concentration c, and binding constant K,, and weak sites 
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59, 106, 108, 124, 126, 136, 143, and 161. For sites 108 124, 
126, 136, and 16 1, the problem seems to be in the experimental 
intensities themselves, which vary irregularly with concen- 
tration. Site 59 is modeled as an enhancement, whereas the 
spot intensity actually remains roughly constant with drug 
concentration for concentrations up to 20 pM and then in- 
creases rapidly to a new constant value approximately double 
the first. The only nearby drug-binding site is the GC at base 
pairs 63-64, which is a strong site, giving binding-type plots 
for sites 62-65. Possibly, the special behavior of site 59 is 
associated with its being on the boundary of the inhibition 
region for this binding site. The data for site 106, which is 
modeled as responding to drug binding to the GCGC at 
101-104, can be better fit by a curve (see Figure 6) such as 
those for sites 85 and 87, which were assumed to be showing 
inhibition due to a very weak and unspecified binding site (K 
= 3 X lo4). However, site 108 appears to be an enhancement 
site, so it is difficult to postulate a weak site to which 106 could 
respond. 
Sites 143 and 145 are modeled as responding to binding at 
the GGC at 143-145. However, experimental intensities seem 
to drop much more abruptly near 20 pM, before leveling off, 
for site 143 than for site 145. This cannot be explained with 
our model, unless it simply reflects large errors in the ex- 
perimental intensities. Also, as noted previously (Goodisman 
& Dabrowiak, 1991, 1992), many footprinting plots show a 
small rapid decrease in intensity with total drug concentration, 
followed by an increase, near 2 pM. Examples in Figure 6 
are sites 85, 87, and 89. This behavior cannot be explained 
in the context of the present model. We have investigated 
(Goodisman & Dabrowiak, 1992) whether this indicates a 
structural change in the DNA like that suggested by other 
workers (Fox & Waring, 1984; Huang et al., 1988; Bishop 
et al., 1991). 
Values of Parameters. We now consider the values of the 
parameters determined by the minimization process. Ac- 
cording to our model, the enhancement E at sites where no 
drug is present is due to the increased probe concentration 
there, caused by drug at the other sites, so that E should be 
inversely proportional to the fraction of the total number of 
probe sites available. The concentration of probe sites (base 
pairs) is about 1 pM. Letting cb be the molar concentration 
of drug bound to the 139-mer and assuming each drug blocks 
seven base pairs, we have 
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E = 1 0-6/ (1 0-6 - 7cb) 
If this is written as (1 - K,cJ1, we find K, = 7 X lo6, close 
to what is determined by minimization. In previous work 
(Ward et al., 1988), we noted larger enhancements at sites 
adjacent to (strong) drug-binding sites. Now that many 
footprinting plots previously considered to be enhancements 
are seen to respond to weak binding sites, only a single site, 
96, appears to show this effect (GC is found at 101-102). 
The carrier, calf thymus DNA, is modeled as having two 
kinds of sites: the strong sites are given a concentration of 
5 pM, as determined from previous calculations which con- 
sidered strong sites only, and the weak-site concentration is 
determined as 10 pM from a series of calculations to determine 
the value that makes D smallest. These values are reasonable, 
although perhaps low, since the 139-mer contains about 6 
strong sites and 11 weak sites in 137 base pairs and the con- 
centration of carrier is 190 FM. The binding constants for 
strong and weak sites on carrier were determined by mini- 
mization of D as 1.1 X lo7 and 4.7 X lo5. That these values 
are higher than the average strong- and weak-site binding 
constants on the fragment may be due to the carrier-site 
Goodisman et al. 
concentrations being too low. Using higher values for these 
concentrations will decrease the carrier binding constants and 
decrease the binding constants for the fragments, but only 
slightly. 
The use of carrier DNA makes it unnecessary to determine 
the concentration of radiolabeled fragment precisely, which 
would be difficult, but it also complicates the analysis. Since 
the structure of the carrier DNA is different from that of the 
radiolabeled fragment, only a fraction of the individual loading 
events taking place in the system are seen on the sequencing 
autoradiogram. However, other analyses have shown that a 
simple model of drug binding to the carrier is sufficient to 
obtain reliable site-specific binding constants toward the 
fragment. For small oligonucleotide duplexes which possess 
a single drug-binding site and which are readily available, 
unlabeled duplex may be used as the carrier. Then, quanti- 
tative analysis of footprinting data is simplified since the only 
loading event taking place is observed on the sequencing au- 
toradiogram, and there are fewer parameters to determine. 
As it becomes easier to purify significant amounts of DNA 
restriction fragments, it will be more practical to use the 
unlabeled fragment as carrier. This will be advisable since 
it ensures that most (not all) of the loading events are seen 
on the autoradiogram, making the modeling of unobserved 
events less important. 
Binding Constants. The binding constants for Act-D at 
specific sites on the 139-mer are given in Table IV. Calculated 
values for log K, are probably reliable to 0.1 in most cases, 
which means Ki is good to 25% and the free energy of binding 
to 0.6 kJ/mol. Values of Ki for the G-label gel are generally 
less reliable because there is more scatter in the data. The 
value for the site at 62-65 is particularly uncertain because 
the site is in a poorly resolved region of the gel and because 
only one footprinting plot is used in its determination. As 
discussed above, the binding constant for the CGCT at 
102-105 is much better determined from the A-label gel than 
from the G-label gel, while the reverse is true for the TGCT 
at 136-139. Aside from these cases, binding constants derived 
from analyses of the two gels generally agree. 
The binding constants are generally higher than what we 
reported in previous work on this system (Rehfuss et al., 
1990b), which analyzed only footprinting data at low drug 
concentrations, but the order of binding constants is not 
changed. As shown above, the reason for larger binding 
constants now is that previous work neglected the weak carrier 
sites, using a total carrier-site concentration of only 5 pM. 
Then, the carrier is saturated with drug when ct gets much 
past 5 pM, and the free-drug concentration rises rapidly with 
total drug concentration. 
The strong sites, with binding constants greater than lo6 
M-I, all possess the 5’-GC-3’ sequence without a preceding 
G, and every such sequence within the region of the fragment 
for which we have footprinting data is a strong binding site, 
except possibly the 5’-TGCCGG-3’ at sites 159-164 (K = 4 
X lo5 M-I). The binding constant for this last site may appear 
low because the site is close to the end of the measurable region 
of the gel, making the experimental data unreliable. More 
likely, it is low because the sequence is 5’-GCC-3’ on the coding 
strand and therefore 5’-GGC-3’ (a typical weak binding site) 
on the noncoding strand. 
The highest binding constant we find on the fragment is 6 
X lo6 M-l, for the sequence 5’-TGCT-3’at 136-139. However, 
the site at 62-65, which has the same sequence, has a binding 
constant of only 4 X lo6 M-l. This indicates that bases 
flanking the tetramer are important in the interaction. Since 
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the drug can span only 4 base pairs of DNA, it is implied that 
Act-D affinity may be affected by changes in DNA structure 
induced by the bases flanking the tetrameric contact sequence. 
Flanking bases may also influence the binding of Act-D to the 
sequence CGCT. On the 139-mer, the 5’-GCGC-3’ sequence 
(sites 101-104) has a binding constant of about 2 X lo6 M-’ 
(Table IV), whereas quantitative footprinting studies of Act-D 
binding to the fragment d(TAGCGCTA)2 (Rehfuss et al., 
1990) return a binding constant of about 4 X lo6 M-l. The 
difference may also be the result of end effects associated with 
short segments of DNA compared to polymeric DNA. 
The site in the vicinity of 130 on the fragment, with sequence 
CCC, is also a relatively strong binding site, with K = 9 X 
lo5 M-’ (this value is somewhat more uncertain than others 
because it comes from data for only one cleavage product). 
Unlike the examples above, it does not possess a core sequence 
having a C, axis of symmetry, like GC, and it is difficult to 
see how the drug, which has a pseudo-C2 symmetry axis, 
interacts with the sequence. In the classical model for binding 
to GC, the two threonine moieties of the drug hydrogen bond 
to the 2-amino groups of both guanines at  the intercalation 
site. The fact that CCC is a strong binding site was previously 
noted in studies with 7-azidoactinomycin D, which is able to 
photocleave DNA (Rill et al., 1989). 
The weak sites, with binding constants between 0.5 X lo5 
M-’ and 9 X lo5 M-’, mostly have the 5’-GGC-3’ sequence. 
Exceptions are the “nonclassical” sequences near 80-84 and 
123-126, discussed below. The reason for the weak binding 
at the GGC sequence is unknown, but it may be related to the 
enhanced stacking interactions of the GG doublet, which re- 
duces the ability of the drug to intercalate at the adjacent GC 
site (Ward et al., 1988). Previous footprinting studies (Ward 
et al., 1988) and studies of cleavage by 7-azidoactinomycin 
D (Rill et al., 1989) also showed that GC doublets were 
strongly preferred only if the 5’-flanking base was a pyrimidine 
and the 3’-flanking base was not cytosine. 
The two weak sites near positions 81 and 124 bind drug but 
do not have a GC core. It is difficult to identify exact in- 
teraction sequences from the footprinting data, but the sites 
both have CCGT and Snyder et al. (1989) have shown that 
Act-D binds with a high binding constant to the duplex d- 
(CGTCGACG)2. However, the CG sequence at 109-110 
shows no tendency to bind Act-D. The sequence CG has 2-fold 
symmetry like GC and thus might hydrogen bond to appro- 
priate sites on the pseudo-2-fold symmetric drug, but this 
would involve reorientation of its cyclic pentapeptide rings 
relative to the phenoxazone chromophore of Act-D if the 
2-amino groups of guanine are used as sequence determinants. 
The relative orientations of the peptide rings of the drug 
outside of DNA are stabilized by specific hydrogen bonds 
between the rings (Ginell et al., 1988), which might prevent 
reOrientation of the peptide ring in DNA, discouraging binding 
of the drug to CG. Like CG, the isolated CC sequence (sites 
115-1 16) shows little tendency to bind drug although CCC 
binds strongly. This suggests that the CGT triplet is required 
for binding. 
CONCLUSIONS 
In this work, we study the binding of the anticancer drug 
actinomycin D to a restriction fragment using quantitative 
footprinting methods. We develop the model which allows 
calculation of theoretical footprinting plots (intensity of each 
spot on the footprinting autoradiogram as a function of drug 
concentration), taking into account equilibria between unbound 
drug and drug bound to sites on the fragment and on calf 
thymus DNA carrier, as well as the enhanced cleavage at sites 
Biochemistry, Vol. 31, No. 4, 1992 1057 
where no drug is bound. A simple model for this mass-action 
enhancement is given. Parameters such as binding constants 
of drug to fragment and carrier sites (Table IV) are deter- 
mined by minimizing the deviation between theoretical and 
experimental footprinting plots. The binding constants for 
Act-D sites on a 139-base-pair restriction fragment are de- 
termined. The highest affinity sites have the dinucleotide 
sequence GC, and of these, those having the sequence TGCT 
have the highest binding constants. Sites having the di- 
nucleotide sequence GC preceded by a G have binding con- 
stants in the range (1-4) X lo5 M-I, about 1 order of mag- 
nitude lower than those of the strong sites. Certain sites which 
do not contain the sequence GC, e.g., CCG and CCC, also 
bind Act-D with a binding constant comparable to those of 
the weak GGC sites. 
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ABSTRACT: In footprinting experiments, an increase in DNA cleavage with addition of ligand to a system 
may be due to a ligand-induced structural change. Ligand binding also enhances cleavage by displacing 
the cleavage agent from ligand-binding sites, thus increasing its concentration elsewhere. The theory and 
characteristics of this mass-action enhancement are given, and it is shown how it may be recognized. Results 
of DNase I footprinting of small oligomers, with actinomycin D as ligand, are analyzed to reveal which 
enhancements are due to mass action, and which can reasonably be ascribed to structural changes. Patterns 
in the footprinting plots from our experiments on actinomycin D binding to a 139-base-pair DNA fragment 
(with DNase I as a probe) are studied in the same way. The likely origins of these patterns are discussed, 
as are enhancements occurring with other probes commonly used in footprinting experiments. 
%e binding of drugs and other ligands may induce structural 
changes in DNA, which may be detected by a number of 
techniques. Since the rate of cleavage at a particular bond 
by agents such as DNase I depends on the local DNA structure 
(Lomonosoff et al., 1981; Drew, 1984; Suck et al., 1988), a 
natural way to study such changes is the footprinting tech- 
nique. In a footprinting experiment, one measures the amounts 
of DNA fragments of different lengths produced by a cleavage 
agent, and hence the amount of cutting taking place at various 
positions on a DNA oligomer, as a function of the ligand 
concentration (Dabrowiak & Goodisman, 1989; Dabrowiak 
et al., 1991). The amount of cutting at positions at or near 
ligand binding sites on DNA will decrease with ligand con- 
centration because the bound ligand prevents the approach of 
the cleavage agent (inhibition), but, at other positions, one 
might expect to see changes in cutting rate due to structural 
changes in the DNA. It should be noted that ligand-induced 
structural changes may lead to increases or decreases in the 
observed cutting rate. Thus, Low et al. (1984) observed large 
enhancements in cutting by DNase I and DNase I1 at many 
sites on a 160-base-pair DNA fragment when echinomycin 
was allowed to bind, in addition to inhibition of cutting near 
the drug binding sites (having the sequence CpG). These 
authors noted two possible explanations for the enhancements: 
structural changes in DNA and an attractive interaction be- 
tween the cleaving protein and the antibiotic, leading to in- 
creased concentration of the former near antibiotic-binding 
sites. They were able to dismiss the latter explanation. 
However, it is now clear (Ward et al., 1988; Dabrowiak & 
Goodisman, 1989; Dabrowiak et al., 1991; Portugal, 1989) that 
there is a third explanation for rate enhancements in DNase 
I footprinting experiments. Increased cutting at sites where 
no ligand binds can arise from a mass-action effect, caused 
by the bound ligand displacing the cleavage agent away from 
some regions of DNA, and thus increasing the concentration 
t We ackowledge the American Cancer Society, Grant NP-681, for 
supporting this research. 
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of cleavage agent elsewhere. This means that one may not 
automatically interpret cleavage rate enhancements as lig- 
and-induced structural changes, since the mass-action effect, 
due to the equilibrium between DNase I and DNA, is always 
present. Since mass-action and structural effects may exist 
simultaneously (Portugal, 1989; Ward et al., 1988), one must 
always consider whether observed enhancements can be ex- 
plained by mass action alone or if they are the result of a 
structural change as well. 
Below, we give a model for the mass-action enhancement 
and discuss how one can judge whether enhancements observed 
in a footprinting experiment have a structural origin. Then, 
we consider observed enhancements on small DNA oligomers 
and longer fragments, previously noted by other workers, which 
may be due to structural changes or mass-action effects. The 
experimentally observed intensity enhancements for actino- 
mycin D interacting with a 139-mer that we believe to be 
structural in origin are then presented and discussed. 
EXPERIMENTAL PROCEDURES 
The quantitative footprinting studies involving actinomycin 
D, the 139-base-pair HindIIIINciI restriction fragment of pBR 
322 DNA, and DNase I were as earlier described (Ward et 
al., 1988). The sequence of the restriction fragment and the 
location of strong and weak actinomycin D binding sites are 
shown in Figure 1. Autoradiographic spot intensities, cor- 
responding to relative amounts of 54 cleavage products of 
different lengths, were measured for 26 actinomycin D con- 
centrations ranging from 0 to 38.8 pM. 
The model used to interpret the resulting footprinting plots, 
plots of spot intensity as a function of total drug concentration, 
is described in detail elsewhere (Goodisman et al., 1992). The 
analysis takes into account binding of drug at the various 
binding sites, the mass-action enhancement, and binding of 
the drug to unlabeled carrier DNA (calf thymus). Correct 
description of the carrier, described as a concentration of strong 
binding sites and a concentration of weak binding sites, is 
important, since it is mainly the equilibria between drug and 
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